30 July 2024 07:00 BST
AstraZeneca prices €1.4
billion bond offering
AstraZeneca PLC (the Company) announces that,
on 29 July 2024, its wholly owned subsidiary AstraZeneca Finance
LLC, successfully priced two tranches of Eurobonds totalling €1.4
billion (the Offering). The Offering is expected to close on 5
August 2024, subject to customary closing conditions.
The Offering consisted of the following notes,
issued by AstraZeneca Finance LLC and fully and unconditionally
guaranteed by the Company:
·
€650 million of fixed rate notes with a coupon of
3.121% maturing on 5 August 2030; and
·
€750 million of fixed rate notes with a coupon of
3.278% maturing on 5 August 2033 (together, the Notes).
The Company expects to use the net proceeds of
the offering for general corporate purposes.
BNP Paribas, Goldman Sachs
International, Morgan Stanley and Société Générale
acted as joint book-running managers on the transaction.
The Notes will be issued under the
US$10,000,000,000 EMTN programme of the Company and AstraZeneca
Finance LLC and admitted to listing on the UK Financial Conduct
Authority's Official List and to trading on the London Stock
Exchange's Main Market.
The Notes have not been registered under the
U.S. Securities Act of 1933 and may not be offered or sold in the
United States absent registration or an applicable exemption from
registration.
This announcement shall not constitute an offer
to sell or the solicitation of an offer to buy the Notes described
herein, nor shall there be any sale of these Notes in any
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such jurisdiction.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is
a global, science-led biopharmaceutical company that focuses on the
discovery, development, and commercialisation of prescription
medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory
& Immunology. Based in Cambridge, UK, AstraZeneca's innovative
medicines are sold in more than 125 countries and used by millions
of patients worldwide. Please visit astrazeneca.com and
follow the Company on social media @AstraZeneca
Contacts
For details on how to contact the
Investor Relations Team, please click here.
For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC